CCM
PTGX icon

Cinctive Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Cinctive Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40,387
Closed -$716K – 635
2021
Q3 		$716K Buy
+40,387
New +$1.72M 0.04% 432

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Cinctive Capital Management's PTGX Position: Q4 2021 in Review

Cinctive Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2021, closing a stake of 40,387 shares — an estimated $716K sold.

Cinctive Capital Management first reported a position in PTGX in Q3 2021 and held it in 1 quarter. The position peaked at $716K in Q3 2021. 149 funds tracked by Wall St. Rank hold PTGX as of Q4 2021.

  • Cinctive Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cinctive Capital Management sold 40,387 Protagonist Therapeutics shares in Q4 2021, an estimated $716K.
  • Cinctive Capital Management first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 1 quarter.
  • Cinctive Capital Management's Protagonist Therapeutics position peaked at $716K in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2021.

Based on Cinctive Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.